Leptomeningeal Disease

Leptomeningeal disease (LMD), also known as leptomeningeal metastases or carcinomatosis, is a devastating complication. No reliable epidemiologic data are available, but it is usually agreed that LMD occurs in approximately 10% of patients with cancer.1 LMD has a very poor prognosis with a median overall survival (OS) of weeks without treatment and a modestly improved OS of 3 to 6.3  months despite multiple therapies.2–11 LMD can affect any part of the central nervous system (CNS) axis and can manifest with a wide variety of clinical signs and symptoms.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research